Head to Head Contrast: Inhibikase Therapeutics (NYSE:IKT) Versus Applied Genetic Technologies (NASDAQ:AGTC)
Head to Head Contrast: Inhibikase Therapeutics (NYSE:IKT) Versus Applied Genetic Technologies (NASDAQ:AGTC)
Inhibikase Therapeutics (NYSE:IKT – Get Rating) and Applied Genetic Technologies (NASDAQ:AGTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Inhibikase Treateutics(纽约证券交易所代码：IKT-GET Rating)和应用基因技术公司(纳斯达克：AGTC-GET Rating)都是小盘医疗公司，但哪一家更好？我们将根据这两家公司的估值、股息、分析师建议、风险、机构所有权、盈利能力和收益的强弱对其进行对比。
Profitability
盈利能力
This table compares Inhibikase Therapeutics and Applied Genetic Technologies' net margins, return on equity and return on assets.
此表比较了Inhibikase治疗公司和应用基因技术公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | -4,894.27% | -51.81% | -46.77% |
| Applied Genetic Technologies | N/A | -98.79% | -60.15% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 抑制酶疗法 | -4,894.27% | -51.81% | -46.77% |
| 应用基因技术 | 不适用 | -98.79% | -60.15% |
Institutional and Insider Ownership
机构和内部人持股
13.3% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 22.1% of Applied Genetic Technologies shares are held by institutional investors. 24.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 4.1% of Applied Genetic Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Inhibikase治疗公司13.3%的股份由机构投资者持有。相比之下，应用基因技术公司22.1%的股份由机构投资者持有。Inhibikase治疗公司24.3%的股份由内部人士持有。相比之下，应用基因技术公司4.1%的股份由内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一家公司有望实现长期增长。
Earnings & Valuation
收益与估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $3.10 million | 7.32 | -$14.79 million | ($0.74) | -1.22 |
| Applied Genetic Technologies | $500,000.00 | 29.42 | -$57.83 million | ($1.46) | -0.20 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 抑制酶疗法 | 310万美元 | 7.32 | -1,479万元 | ($0.74) | -1.22 |
| 应用基因技术 | $500,000.00 | 29.42 | -5783万美元 | ($1.46) | -0.20 |
Inhibikase Therapeutics has higher revenue and earnings than Applied Genetic Technologies. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.
Inhibikase治疗公司的收入和收益比应用基因技术公司高。Inhibikase治疗公司的市盈率低于应用基因技术公司，这表明它目前是两只股票中更负担得起的一只。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings for Inhibikase Therapeutics and Applied Genetic Technologies, as provided by MarketBeat.com.
这是MarketBeat.com提供的Inhibikase治疗技术和应用基因技术最近的评级细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Applied Genetic Technologies | 0 | 1 | 4 | 0 | 2.80 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 抑制酶疗法 | 0 | 0 | 0 | 0 | 不适用 |
| 应用基因技术 | 0 | 1 | 4 | 0 | 2.80 |
Applied Genetic Technologies has a consensus target price of $6.50, indicating a potential upside of 2,141.38%. Given Applied Genetic Technologies' higher possible upside, analysts clearly believe Applied Genetic Technologies is more favorable than Inhibikase Therapeutics.
应用基因技术公司的共识目标价为6.50美元，表明潜在涨幅为2,141.38%。考虑到应用基因技术的更高可能的上行空间，分析人士显然认为应用基因技术比Inhibikase治疗更有利。
Volatility and Risk
波动性和风险
Inhibikase Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Inhibikase Treateutics的贝塔系数为1.19，这意味着其股价的波动性比标准普尔500指数高19%。相比之下，应用基因技术公司的贝塔系数为1.26，这意味着其股价的波动性比标准普尔500指数高26%。
Summary
摘要
Applied Genetic Technologies beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks.
应用基因技术公司在两只股票之间的13个因素中有7个超过了Inhibikase治疗公司。
About Inhibikase Therapeutics
关于Inhibikase疗法
(Get Rating)
(获取评级)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
临床阶段制药公司Inhibikase Treateutics，Inhibikase Treeutics，Inhibikase Treateutics，Inhibikase Treateutics，Inc.是一家临床阶段制药公司，开发帕金森氏病(PD)和大脑内外相关疾病的疗法。该公司的候选产品包括用于治疗帕金森氏症以及帕金森氏症早期症状(如吞咽、吞咽困难、神经原性便秘和多系统萎缩)的小分子阿贝尔森酪氨酸激酶抑制剂IKT-148009；以及抗癌药物伊马替尼的前药IKT-001Pro，该药物正处于临床前开发阶段，旨在将胃肠道副作用降至最低，并用于治疗血液和胃癌。它还参与开发其他神经疾病的各种研究计划。该公司与约翰·霍普金斯大学、亚利桑那州立大学、密歇根州立大学以及路易斯安那州立大学有研发合作。Inhibikase治疗公司成立于2008年，总部设在佐治亚州亚特兰大。
About Applied Genetic Technologies
关于应用基因技术
(Get Rating)
(获取评级)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
应用基因技术公司是一家临床阶段的生物技术公司，为患有罕见和衰弱疾病的患者开发变革性基因疗法。其先进的候选产品包括两个目标的三个眼科开发计划，包括正在进行I/II阶段临床试验的X连锁视网膜色素变性；以及正在进行I/II阶段临床试验的色盲。该公司还在开发一种候选光遗传产品，用于治疗晚期视网膜疾病。此外，该公司还启动了一个耳科临床前项目；以及两个针对中枢神经系统疾病的临床前项目，包括额颞痴呆和肌萎缩侧索硬化症。它与佛罗里达大学、仿生视觉有限责任公司和Otmey公司签订了合作协议。应用基因技术公司成立于1999年，总部设在佛罗里达州阿拉丘亚市。
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Inhibikase治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Inhibikase Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。